The European Medicines Agency (EMA) has set out guiding principles for its newly-formed COVID-19 EMA pandemic Task Force (COVID-ETF).
The group will be tasked with helping EU countries to handle the development, authorization and safety monitoring of therapeutics and vaccines intended for treatment or prevention of COVID-19.
COVID-ETF has been formed under the EMA’s health threat plan, with the purpose of drawing on the expertise of regulators and all other parties to ensure a fast and coordinated response to the pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze